Rapid diagnosis and tumor margin assessment during pancreatic cancer surgery with the MasSpec Pen technology
Mary E King,Jialing Zhang,John Q Lin,Kyana Y Garza,Rachel J DeHoog,Clara L Feider,Alena Bensussan,Marta Sans,Anna Krieger,Sunil Badal,Michael F Keating,Spencer Woody,Sadhna Dhingra,Wendong Yu,Christopher Pirko,Kirtan A Brahmbhatt,George Van Buren,William E Fisher,James Suliburk,Livia S Eberlin,Mary E. King,John Q. Lin,Kyana Y. Garza,Rachel J. DeHoog,Clara L. Feider,Michael F. Keating,Kirtan A. Brahmbhatt,William E. Fisher,Livia S. Eberlin
DOI: https://doi.org/10.1073/pnas.2104411118
IF: 11.1
2021-07-06
Proceedings of the National Academy of Sciences
Abstract:Significance Surgical removal of pancreatic cancer remains the only option for a cure. To verify the extent of tumor removal, surgeons rely on pathologic evaluation of frozen sections of surgical margins. However, this process can be challenging, time consuming, and subjective. Here, we used the MasSpec Pen to rapidly distinguish pancreatic cancer from healthy pancreatic and bile duct tissues by generating classification models based on the molecular signatures acquired from tissue. We evaluated this technology in an operating room during pancreatic surgeries and used these classification models to predict on data obtained in vivo and ex vivo with high performance. Our results suggest that the MasSpec Pen platform has the potential to improve and expedite margin evaluation during pancreatic cancer surgery.
multidisciplinary sciences